Coronado Biosciences to Present at the Jefferies 2013 Global Healthcare Conference BURLINGTON, Mass., May 28, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today that Dr. Harlan F. Weisman, Coronado's Chairman and CEO, will present at the Jefferies 2013 Global Healthcare Conference on Monday, June 3, 2013, at 1:00 PM ET. The conference will be held at the Grand Hyatt New York on June 3-6, 2013. A webcast of the presentation will be available at www.coronadobiosciences.com on the Events & Webcasts page. About Coronado Biosciences Coronado Biosciences is engaged in the development of novel immunotherapy biologic agents. The company's two principal pharmaceutical product candidates in clinical development are: TSO (Trichuris suis ova or CNDO-201), a biologic for the treatment of autoimmune diseases, such as Crohn's disease, ulcerative colitis and multiple sclerosis; and CNDO-109, a biologic that activates natural killer (NK) cells, for the treatment of acute myeloid leukemia (AML), multiple myeloma and solid tumors. For more information, please visit www.coronadobiosciences.com. CONTACT: Lucy Lu, MD, Executive Vice President & Chief Financial Officer Coronado Biosciences, Inc. 781-652-4525; email@example.com Marcy Nanus, Vice President The Trout Group, LLC. 646-378-2927; firstname.lastname@example.org Susan Forman Dian Griesel Inc. 212-825-3210; email@example.com Coronado Biosciences logo
Coronado Biosciences to Present at the Jefferies 2013 Global Healthcare Conference
Press spacebar to pause and continue. Press esc to stop.